AcelRx Pharmaceuticals, Inc. (ACRX) Insider Lawrence G. Hamel Sells 10,161 Shares
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) insider Lawrence G. Hamel sold 10,161 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $5.29, for a total value of $53,751.69. Following the transaction, the insider now owns 16,379 shares in the company, valued at approximately $86,644.91. The sale was disclosed in a document filed with the SEC, which is available through this link.
Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ ACRX) remained flat at $5.50 during mid-day trading on Tuesday. The company had a trading volume of 3,881,862 shares. AcelRx Pharmaceuticals, Inc. has a 52-week low of $1.95 and a 52-week high of $5.75. The stock’s market capitalization is $249.59 million. The stock has a 50 day moving average price of $3.44 and a 200-day moving average price of $2.88.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its quarterly earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.01). The firm had revenue of $2.66 million during the quarter, compared to analyst estimates of $2.63 million. On average, equities research analysts predict that AcelRx Pharmaceuticals, Inc. will post ($1.13) earnings per share for the current year.
Several brokerages recently commented on ACRX. Jefferies Group LLC reissued a “buy” rating and issued a $7.00 price target on shares of AcelRx Pharmaceuticals in a report on Friday, July 14th. Royal Bank Of Canada set a $6.00 price objective on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 25th. Roth Capital reaffirmed a “buy” rating and set a $12.50 price objective on shares of AcelRx Pharmaceuticals in a report on Thursday, August 10th. Stifel Nicolaus raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of AcelRx Pharmaceuticals in a research report on Friday, August 4th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.93.
A number of hedge funds and other institutional investors have recently modified their holdings of ACRX. Goldman Sachs Group Inc. purchased a new position in AcelRx Pharmaceuticals during the 2nd quarter valued at about $530,000. WealthTrust Axiom LLC raised its position in AcelRx Pharmaceuticals by 50.0% during the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock worth $451,000 after acquiring an additional 70,000 shares during the last quarter. LMR Partners LLP acquired a new position in AcelRx Pharmaceuticals during the second quarter worth about $319,000. Virtu KCG Holdings LLC raised its position in AcelRx Pharmaceuticals by 600.9% during the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after acquiring an additional 101,742 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in AcelRx Pharmaceuticals by 6.6% during the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock worth $355,000 after acquiring an additional 6,942 shares during the last quarter. 23.32% of the stock is currently owned by hedge funds and other institutional investors.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.